Evidence-based Mobile Medical Applications in Diabetes.
This article reviews mobile medical applications that are commercially available in the United States or European Union (EU) and are (1) associated with published data of clinical outcomes in the peer-reviewed literature during the past 5 years, (2) cleared by the US Food and Drug Administration (FDA) in the United States, or (3) a recipient of a CE (Conformité Européenne) mark by the EU. Many of these applications have been shown to positively affect outcomes in the short term, but long-term studies are needed. Until more data are available, consumers and professionals can consider guidance based on FDA/CE status.
Nebraska Medicine, Diabetes Center, 4400 Emile Street, Omaha, NE 68198, USA. Electronic address: andjela.drincic@unmc.edu.
Andjela
A
Drincic
Division of Endocrinology and Diabetes, Pediatrics, Stanford University, 300 Pasteur Drive, Room G313, MC 5208, Stanford, CA 94305, USA.
Priya
P
Prahalad
Sutter Health Integrated Diabetes Education Network, Quality and Clinical Effectiveness Team, Office of Patient Experience, Sutter Health, 2200 River Plaza Drive, Sacramento, CA 95833, USA.
Deborah
D
Greenwood
Diabetes Research Institute, Mills-Peninsula Health Services, 100 South San Mateo Drive, Room 5147, San Mateo, CA 94401, USA.
David C
DC
Klonoff
D003920:Diabetes Mellitus / Q000628:therapy*; D005062:European Union; D019317:Evidence-Based Medicine; D006801:Humans; D063731:Mobile Applications; D014481:United States
Applications; Diabetes; Glucose; Medical; Mobile; Telemedicine; mHealth